How many months after the last dose of Reclast (zoledronic acid) can a patient undergo tooth extraction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of Tooth Extraction After Reclast (Zoledronic Acid)

For patients on Reclast for osteoporosis, some experts recommend stopping the medication 2 months before tooth extraction to allow better bone healing, though the evidence supporting this drug holiday remains controversial and unproven. 1

Risk Context for Osteoporosis Patients

The risk of osteonecrosis of the jaw (ONJ) with Reclast for osteoporosis is substantially lower than with cancer-dose bisphosphonates:

  • Oral bisphosphonates for osteoporosis carry a very rare ONJ risk of less than 1 case per 100,000 person-years 1
  • Intravenous bisphosphonates like Reclast for cancer treatment have a 6.7-11% ONJ incidence, which is dramatically higher than osteoporosis dosing 2, 1
  • The fracture prevention benefits of continued bisphosphonate therapy generally outweigh the minimal ONJ risk in osteoporosis patients 1

Evidence-Based Timing Recommendations

The 2-Month Drug Holiday Approach

  • The American Society of Clinical Oncology discusses that stopping bisphosphonates 2 months prior to oral surgery may hypothetically allow better bone healing, with resumption delayed until adequate healing occurs 1
  • However, this same guideline acknowledges that a short break may have no effect on bone healing since bone effects of bisphosphonates are maintained for years after treatment stops 1
  • The effectiveness of short-term drug holidays has not been confirmed in research studies 3

Alternative Timing Strategy

  • In one study of denosumab (a similar bone-modifying agent), 76 patients who had extractions between 6-7 months after the last injection developed zero cases of ONJ 4
  • This suggests that timing extractions toward the end of the dosing interval (when drug levels are lowest) may reduce risk 4

Critical Pre-Extraction Protocol

Regardless of timing decisions, these steps are mandatory:

  • Complete comprehensive dental evaluation and all necessary invasive dental procedures BEFORE initiating Reclast whenever possible—this eliminates ONJ risk entirely 1
  • Use prophylactic antibiotics perioperatively 1
  • Maintain excellent oral hygiene throughout treatment 1
  • Defer resumption of Reclast until complete healing from the dental procedure is confirmed by the dentist 1

Risk Factors That Increase ONJ Likelihood

  • Recent dental surgery or extraction is the most consistent risk factor for ONJ 1
  • Longer duration of bisphosphonate exposure increases risk, with cumulative hazard rising from 1% at 12 months to 11-13% at 4 years 1
  • Root amputation, mandibular tooth extraction, and pre-existing inflammation significantly increase ONJ risk 3

Practical Algorithm

For elective extractions in osteoporosis patients on Reclast:

  1. If possible, delay extraction and optimize the tooth conservatively 1
  2. If extraction is necessary, consider stopping Reclast 2 months before the procedure 1
  3. Schedule extraction 6-7 months after the last Reclast dose if drug holiday is not feasible (extrapolated from 4)
  4. Use prophylactic antibiotics and meticulous surgical technique 1
  5. Do not resume Reclast until socket healing is radiographically and clinically complete 1

Important Caveat

The 2-month drug holiday recommendation lacks robust validation and may provide no actual benefit given bisphosphonates' prolonged skeletal retention 1. The decision must weigh the patient's fracture risk against the minimal ONJ risk, recognizing that maintaining bone protection may be more important than an unproven drug holiday in most osteoporosis patients 1.

References

Guideline

Bisphosphonate Discontinuation and Osteonecrosis of the Jaw Risk

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019

Research

What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.